NLS Pharmaceutics .(NLSP) - 2022 Q4 - Annual Report

Report of Foreign Private Issuer on Form 6-K Management Change Mr. Chad Hellmann resigned as CFO of NLS Pharmaceutics Ltd. on May 1, 2023, providing transition services until May 31, 2023 - Mr. Chad Hellmann resigned as the Chief Financial Officer on May 1, 2023[4] - Mr. Hellmann will provide transition services to the company through May 31, 2023[4] - The resignation was not based on any material disagreement with the company on any matter relating to its operations, policies, or practice[4] Incorporation by Reference This Form 6-K report is incorporated by reference into the company's Registration Statements on Form F-3, including specified file numbers - The Form 6-K is incorporated by reference into the Registrant's Registration Statements on Form F-3 with file numbers 333-262489, 333-268690, and 333-269220[5] Signatures The report was duly authorized and signed on May 5, 2023, by Alexander Zwyer, Chief Executive Officer of NLS Pharmaceutics Ltd - The report was signed on May 5, 2023, by Alexander Zwyer, Chief Executive Officer[9]